Publication Name	World Journal of Cardiology
Manuscript ID	73160
Country	Greece

Received	2021-11-11 12:55
Peer-Review Started	2021-11-11 12:57
To Make the First Decision
Return for Revision	2021-12-27 02:50
Revised	2021-12-29 11:00
Second Decision	2022-03-10 05:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-03-17 04:18
Articles in Press	2022-03-17 04:18
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-03-08 01:17
Typeset the Manuscript	2022-04-11 09:31
Publish the Manuscript Online	2022-04-19 03:18

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Letter to the Editor
Article Title	Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
Manuscript Source	Invited Manuscript
All Author List	Angeliki Bourazana, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis and Andrew Xanthopoulos
ORCID	Author(s) ORCID Number Angeliki Bourazana http://orcid.org/0000-0001-8297-4201 Grigorios Giamouzis http://orcid.org/0000-0002-7406-5427 John Skoularigis http://orcid.org/0000-0001-7159-2478 Filippos Triposkiadis http://orcid.org/0000-0001-6433-4016 Andrew Xanthopoulos http://orcid.org/0000-0002-9439-3946
Funding Agency and Grant Number
Corresponding Author	Andrew Xanthopoulos, FACC, MD, PhD, Doctor, Doctor, Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com
Key Words	Dipeptidyl peptidase-4 inhibitors; Diabetes mellitus; Outcomes; Meta-analysis; Heart failure; Atrial flutter
Core Tip	Dipeptidyl peptidase-4 inhibitors are a safe and effective glucose lowering treatment option in patients with type 2 diabetes mellitus. However, their effect on cardiovascular outcomes in diabetic patients has been neutral. The potential correlation between atrial flutter and dipeptidyl peptidase-4 inhibitors administration is an interesting finding, but since currently there is no sheer underlying pathophysiologic mechanism to justify it, more evidence is required.
Publish Date	2022-04-19 03:18
Citation	Bourazana A, Giamouzis G, Skoularigis J, Triposkiadis F, Xanthopoulos A. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World J Cardiol 2022; 14(4): 266-270
URL	https://www.wjgnet.com/1949-8462/full/v14/i4/266.htm
DOI	https://dx.doi.org/10.4330/wjc.v14.i4.266

Full Article (PDF)	WJC-14-266.pdf
Full Article (Word)	WJC-14-266.docx
Manuscript File	73160_Auto_Edited-YJM-FilipodiaCL.docx
Answering Reviewers	73160-Answering reviewers.pdf
Audio Core Tip	73160-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	73160-Conflict-of-interest statement.pdf
Copyright License Agreement	73160-Copyright license agreement.pdf
Peer-review Report	73160-Peer-review(s).pdf
Scientific Editor Work List	73160-Scientific editor work list.pdf
CrossCheck Report	73160-CrossCheck report.pdf